All In Biotech

NDA 208692 · Exelixis INC

Cabometyx

Cabozantinib S-Malate · Oral

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 25, 2016

Approved uses

8

Original approval plus efficacy supplements

Registered trials

45

3 Phase 3, 6 recruiting

FAERS reports

45,867

20,559 serious, 5,123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 19, 2025.

CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab ( 1.1 ) patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.2 ) adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible ( 1.3 ) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET). ( 1.4 ) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET). ( 1.4 ) 1.1 Renal Cell Carcinoma CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced RCC. 1.2 Hepatocellular Carcinoma CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. 1.3 Differentiated Thyroid Cancer CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. 1.4 Neuroendocrine Tumors CABOMETYX is indicated for the treatment of adult and pediatric...

Mechanism: In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 10, 2025 Supplement 18 · Efficacy OrphanLetterLabel
  • Mar 26, 2025 Supplement 17 · Efficacy OrphanLabelLetter
  • Jul 14, 2022 Supplement 14 · Efficacy LetterLabel
  • Sep 17, 2021 Supplement 12 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jan 22, 2021 Supplement 10 · Efficacy · priority review LabelLetter
  • Jan 14, 2019 Supplement 3 · Efficacy OrphanLabelLetter
  • Dec 19, 2017 Supplement 2 · Efficacy · priority review LabelLetter
  • Apr 25, 2016 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyOrphanLabelReviewOther
3 products under this application
  • CABOMETYX · CABOZANTINIB S-MALATE EQ 60MG BASE · TABLET, ORAL · Prescription · TE AB
  • CABOMETYX · CABOZANTINIB S-MALATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • CABOMETYX · CABOZANTINIB S-MALATE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Cabozantinib S-Malate" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea8,923
  • fatigue7,330
  • off label use6,092
  • nausea4,724
  • decreased appetite4,414
  • malignant neoplasm progression3,284
  • blood pressure increased3,107
  • palmar-plantar erythrodysaesthesia syndrome3,042
  • weight decreased2,872
  • death2,797
  • stomatitis2,731
  • constipation2,284

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20123
201316
2014107
201587
2016159
20171,452
20183,369
20193,853
20202,940
20214,546
20225,885
20236,053
20246,461
20256,037
20264,898

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cabometyx (Cabozantinib S-Malate)

2024 spending

$1.22B

Beneficiaries

9,182

50,232 claims

Per beneficiary

$132,512

$826.87 per unit

View as table
YearSpending
2020$380,754,686
2021$662,754,254
2022$919,262,057
2023$1,109,315,042
2024$1,216,725,023

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Exelixis INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.